References
- WHO. Global status report on noncommunicable diseases 2014. Geneva: World Health Organization; 2014.
- CDC. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta (GA): U.S. Department of Health and Human Services; 2014.
- ADA. Standards of medical care in diabetes – 2016. J Clin App Res Edu. 2016;39(S1):1–112.
- Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32(S32):S151–S156. doi: 10.2337/dc09-S301.
- Kim SC, Glynn RJ, Liu J, Everett BM, Goldfine AB. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol. 2014;51(6):1015–1023.
- Tran L, Zielinski A, Roach AH, et al. Pharmacologic treatment of type 2 diabetes: oral medications. Ann Pharmacother. 2015;49(5):540–556. doi: 10.1177/1060028014558289.
- Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2016;40(4):468–475.
- Crickx E, Marroun I, Veyrie C, et al. DPP4 inhibitor-induced polyarthritis: a report of three cases. Rheumatol Int. 2014;34(2):291–292. doi: 10.1007/s00296-013-2710-7.
- Yokota K, Igaki N. Sitagliptin (DPP-4 Inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report. Intern Med. 2012;51(15):2041–2044. doi: 10.2169/internalmedicine.51.7592.
- Sasaki T, Hiki Y, Nagumo S, et al. Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus. Diabetol Int. 2010;1(2):90–92. doi: 10.1007/s13340-010-0010-y.
- Chaicha-Brom T, Yasmeen T. DPP-IV inhibitor-associated arthralgias. Endocr Pract. 2013;19(2):377
- Tarapués M, Cereza G, Figueras A. Association of musculoskeletal complaints and gliptin use: review of spontaneous reports. Pharmacoepidemiol Drug Saf. 2013;22:1115–1118.
- FDA. (2015, August 28). Drug Safety and Availability. Retrieved from United States Food and Drug Administration: http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm
- Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients with Type 2 Diabetes. Diabetes Care. 2006;29(12):2632–2637. doi: 10.2337/dc06-0703.
- García-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–194. doi: 10.1007/s13300-013-0034-y.
- Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10. doi: 10.2307/2137284.
- Mascolo A, Rafaniello C, Sportiello L, et al. Dipeptidyl Peptidase (DPP)-4 inhibitor-induced arthritis/arthralgia: a review of clinical cases. Drug Saf. 2016;39(5):401–407. doi: 10.1007/s40264-016-0399-8.
- Huh S, Rice T, Ettner SL. Prescription drug coverage and effects on drug expenditures among elderly medicare beneficiaries. Health Serv Res. 2007;43(3):810–832. doi: 10.1111/j.1475-6773.2007.00804.x.
- Mahendraratnam N, Dusetzina SB, Farley JF. Prescription drug utilization and reimbursement increased following state medicaid expansion in 2014. J Manag Care Spec Pharm. 2017;23(3):355–363. doi: 10.18553/jmcp.2017.23.3.355.
- Park YJ, Martin EG. Medicare part D’s effects on drug utilization and out-of-pocket costs: a systematic review. Health Serv Res. 2017;52(5):1685–1728.
- American diabetes association. Economic costs of diabetes in the US in 2012. Diabetes Care. 2013;36(4):1033–1046.
- Scirica BM, Braunwald E, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–1588. doi: 10.1161/CIRCULATIONAHA.114.010389.
- Green JB, Bethel MA, Armstrong PW, TECOS Study Group, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352.
- Eurich D, Simpson S, Senthilselvan A, Asche C, Sandhu-Minhas J, McAlister F. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ. 2013;346:f2267.